The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 107.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The claim credit process and conference evaluation will be available online starting Sept. 10 through Dec. 31, 2024, in the IASLC Lung Cancer 360. Log in using your Lung Cancer 360 Username and Password, select the sessions you attended, complete the conference evaluation, and download your certificate. If you are new to Lung Cancer 360 or forgot your password, click the Reset Password link. For assistance, please email [email protected].
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 107.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.
The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians.
The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.
In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity.
All disclosures will be available to participants via the conference app and on the conference website.
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.
The IASLC 2024 World Conference on Lung Cancer (WCLC 2024) is the world’s largest international conference for clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2024 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts and posters.
The IASLC 2024 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.
At the conclusion of this activity, participants will be able to:
The official language of the IASLC 2024 World Conference on Lung Cancer is English.
The information presented at the IASLC 2024 World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Check out our FAQ page for answers or contact us